Cargando…

Diagnosis and treatment of ECL cell tumors.

The diagnosis of ECL-omas is easy to perform. In patients with Zollinger-Ellison syndrome (ZES), ECL-omas are almost always observed in the setting of multiple endocrine neoplasia type I. In patients without ZES, the first step is to discard non-gastrin-related sporadic ECL-omas whose prognosis is p...

Descripción completa

Detalles Bibliográficos
Autores principales: Cadiot, G., Cattan, D., Mignon, M.
Formato: Texto
Lenguaje:English
Publicado: Yale Journal of Biology and Medicine 1998
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2578988/
https://www.ncbi.nlm.nih.gov/pubmed/10461362
_version_ 1782160550574161920
author Cadiot, G.
Cattan, D.
Mignon, M.
author_facet Cadiot, G.
Cattan, D.
Mignon, M.
author_sort Cadiot, G.
collection PubMed
description The diagnosis of ECL-omas is easy to perform. In patients with Zollinger-Ellison syndrome (ZES), ECL-omas are almost always observed in the setting of multiple endocrine neoplasia type I. In patients without ZES, the first step is to discard non-gastrin-related sporadic ECL-omas whose prognosis is poor. By contrast, prognosis of ECL-omas in patients with ZES or chronic atrophic gastritis is good. Metastases are rare, and tumor-related deaths are exceptional. In both conditions, ECL-omas measuring less than 1 cm should be treated by endoscopic polypectomy and survey. Treatment modalities (surgery, endoscopic polypectomy) for larger tumors are still discussed. The impact of endoscopic ultrasonography on the therapeutic decision has not yet been evaluated. Considering the good prognosis of these tumors, aggressive surgery could be limited to selected patients. Multicentric studies should be undertaken to determine the best treatment modalities.
format Text
id pubmed-2578988
institution National Center for Biotechnology Information
language English
publishDate 1998
publisher Yale Journal of Biology and Medicine
record_format MEDLINE/PubMed
spelling pubmed-25789882008-11-05 Diagnosis and treatment of ECL cell tumors. Cadiot, G. Cattan, D. Mignon, M. Yale J Biol Med Research Article The diagnosis of ECL-omas is easy to perform. In patients with Zollinger-Ellison syndrome (ZES), ECL-omas are almost always observed in the setting of multiple endocrine neoplasia type I. In patients without ZES, the first step is to discard non-gastrin-related sporadic ECL-omas whose prognosis is poor. By contrast, prognosis of ECL-omas in patients with ZES or chronic atrophic gastritis is good. Metastases are rare, and tumor-related deaths are exceptional. In both conditions, ECL-omas measuring less than 1 cm should be treated by endoscopic polypectomy and survey. Treatment modalities (surgery, endoscopic polypectomy) for larger tumors are still discussed. The impact of endoscopic ultrasonography on the therapeutic decision has not yet been evaluated. Considering the good prognosis of these tumors, aggressive surgery could be limited to selected patients. Multicentric studies should be undertaken to determine the best treatment modalities. Yale Journal of Biology and Medicine 1998 /pmc/articles/PMC2578988/ /pubmed/10461362 Text en
spellingShingle Research Article
Cadiot, G.
Cattan, D.
Mignon, M.
Diagnosis and treatment of ECL cell tumors.
title Diagnosis and treatment of ECL cell tumors.
title_full Diagnosis and treatment of ECL cell tumors.
title_fullStr Diagnosis and treatment of ECL cell tumors.
title_full_unstemmed Diagnosis and treatment of ECL cell tumors.
title_short Diagnosis and treatment of ECL cell tumors.
title_sort diagnosis and treatment of ecl cell tumors.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2578988/
https://www.ncbi.nlm.nih.gov/pubmed/10461362
work_keys_str_mv AT cadiotg diagnosisandtreatmentofeclcelltumors
AT cattand diagnosisandtreatmentofeclcelltumors
AT mignonm diagnosisandtreatmentofeclcelltumors